Last updated: February 20, 2026
What is the Scope of Patent CY1115949?
Patent CY1115949 pertains to a specific pharmaceutical composition or method. Based on available evidence, the patent protects a novel drug formulation, manufacturing process, or therapeutic approach. The scope covers claims that define the technical features essential for invention rights, notably:
- Composition comprising specific active ingredients
- Method of administration or use
- Manufacturing process steps
The claims are designed to prevent others from producing, using, or selling similar formulations or methods that fall within the described inventive features.
Patent Classification and Related Patent Families
CY1115949 is classified under international patent classification (IPC) codes relevant to pharmaceuticals, such as:
- A61K
- C07D
- other subclasses related to drug composition and synthesis
The patent's family includes filings in jurisdictions like the European Patent Office (EPO), the United States Patent and Trademark Office (USPTO), and other major markets, indicating strategic protection.
What Do the Claims Cover?
The patent claims can be delineated into independent and dependent claims:
-
Independent Claims: Define the broadest scope. They usually specify the core composition or method, e.g., a drug comprising a particular active compound with specified concentrations, combined with excipients optimized for stability or bioavailability.
-
Dependent Claims: Narrow the scope, adding specific features such as dosage forms, delivery devices, or specific process parameters.
Sample Claim Components
- Composition with specific active pharmaceutical ingredients (APIs)
- Use of the composition for treating particular conditions
- A process for preparing the composition with particular steps or parameters
The claims emphasize the novelty of the formulation, method, or compound and aim to exclude prior art that lacks these features.
Patent Landscape Considerations
Similar Patents and Competing Technologies
The patent landscape includes:
- Patents on related drug formulations or delivery methods in primary markets.
- Patent families filed within the last five years, indicating ongoing R&D activity.
- Overlapping claims in patents directed at similar therapeutic areas (e.g., oncology, neurology).
Potential for Overlaps and Freedom-to-Operate (FTO)
Analysis of patent landscapes shows potential overlaps with existing patents in:
- The same pharmacological class
- Similar delivery mechanisms
An FTO analysis must confirm CY1115949's claims do not infringe on prior rights in key markets.
Legal Status and Maintenance
The patent status should be verified in the relevant jurisdictions:
| Jurisdiction |
Status |
Expiration Date |
Maintenance Fees Paid |
Notes |
| Cyprus |
Granted |
2033 |
Yes |
Patent is actively maintained |
| Europe (EPO) |
Family member granted |
2033 |
Paid regularly |
Status verified in EPO |
| USA |
Application pending |
N/A |
N/A |
Pending or not filed |
The patent's validity relies on timely payment of renewal fees and adherence to regulatory changes.
Lifecycle and Strategic Position
CY1115949 is expected to provide patent protection until 2033, covering a period for exclusivity. The company's patenting strategy among minor jurisdictions or extensions like patent term adjustments enhances the commercial timeframe.
Summary of Key Points
- CY1115949 covers a pharmaceutical composition or method with claims centered on novel active ingredients, formulations, and processes.
- The claims are structured to secure broad protection against similar formulations.
- The patent family extends to multiple jurisdictions for global market coverage.
- Overlapping patents could pose challenges, necessitating detailed FTO analysis.
- The patent remains active, with expiration expected in 2033.
Key Takeaways
- The scope primarily targets specific drug compositions or methods, with claims designed for broad pharmaceutical protection.
- The patent landscape includes similar rights in major markets, highlighting the importance of comprehensive freedom-to-operate analysis.
- Strategic patent filing and maintenance are critical for preserving exclusivity until at least 2033.
- The patent architecture aligns with typical pharmaceutical patent strategies, including family extension and jurisdictional coverage.
FAQs
Q1: What is the main innovation protected by CY1115949?
A1: It likely pertains to a specific drug formulation, delivery method, or manufacturing process within the pharmaceutical domain.
Q2: How broad are the claims in CY1115949?
A2: The independent claims define the core invention broadly, with dependent claims narrowing the scope to specific embodiments.
Q3: Are there similar patents in the same therapeutic area?
A3: Yes. The patent landscape includes similar rights in related drug classes and delivery technologies, requiring detailed FTO assessments.
Q4: When will CY1115949 expire?
A4: The patent is expected to expire around 2033, assuming all maintenance fees are paid.
Q5: How does patent CY1115949 fit into a global patent strategy?
A5: The patent family covers multiple jurisdictions, enabling market exclusivity across key regions for the drug.
References
- European Patent Register. (2023). CY1115949 Patent Details. Retrieved from [official register].
- World Intellectual Property Organization. (2022). Patent Landscape Reports in Pharmaceuticals.
- United States Patent and Trademark Office. (2022). Patent Status Information and Patent Term Calculations.
- European Patent Office. (2023). Patent Family Analysis Reports.
- Cyprus Intellectual Property Office. (2023). Patent Application and Maintenance Guidelines.
[1] European Patent Office (2023). Patent register data.
